Maximizing immunogenicity

Why OncoQR thinks its S-TIR vaccine can work better than other cancer vaccines

OncoQR ML is developing allogeneic cancer vaccines that use S-TIR active immunotherapy technology to increase immunogenicity compared with earlier approaches.

According to co-founder, Managing Director and COO Christof Langer, the company's "warhead" approach enables a much more potent immune response to S-TIR vaccines than other allogeneic cancer vaccines, which use a variety of immune stimulators including toll-like receptor 9 (TLR9) agonists. The warhead consists of a peptide with moieties targeting both TLR9 and Fc gamma receptor II (FCGRA2; CD32), and

Read the full 801 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers